Posted by: Thixia | February 25, 2009

Oral Laquinimod for Multiple Sclerosis Granted Fast Track

Press Release


Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA


Jerusalem, Israel and Lund, Sweden, February 12, 2009




Teva Pharmaceutical Industries Ltd.  (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS), has received a Fast Track designation from the U.S.  Food and Drug Administration (FDA).  Teva completed enrollment for the first of its two Phase III clinical trials for laquinimod (ALLEGRO) in November 2008 and is currently enrolling RRMS patients globally for the second Phase III study (BRAVO).




Drugs designated for Fast Track are intended for the treatment of a serious or life-threatening condition and have demonstrated the potential to address unmet medical needs.  Fast Track designation can potentially facilitate development and expedite the review process.  This may allow the drug to enter the market as soon as late 2011.




“As global leaders in the treatment of multiple sclerosis, Teva is committed to bringing additional safe, effective and convenient therapies to MS patients,” said Moshe Manor, Vice President, Global Innovative Resources Group at Teva.  “We are pleased that the FDA has awarded laquinimod with a Fast Track designation, and are hopeful it will be part of our growing portfolio of innovative therapies.”




“We’re encouraged by the reports we’ve seen from the Phase II clinical trial of laquinimod, and if this agent continues to prove safe and effective, it would be a welcome new treatment option available to people with multiple sclerosis,” said Dr.  John Richert, Executive Vice President, Research and Clinical Programs, National MS Society.




Laquinimod is a novel, once-daily, orally administered immunomodulatory compound being studied as a disease-modifying treatment for RRMS.  For more information on the ongoing laquinimod Phase III clinical program, please visit or call 1-800-840-5601 in the US and 1-800-283-0034 in Canada. 






About Laquinimod




Laquinimod is a novel once-daily, orally administered immunomodulatory compound that is being developed as a disease-modifying treatment for RRMS.  Active Biotech developed laquinimod and licensed it to Teva Pharmaceutical Industries, Ltd. in June 2004.  Results from a Phase IIb study in 306 patients were published in June 2008 in The Lancet and reported that an oral 0.6 mg dose of laquinimod, administered daily, significantly reduced MRI disease activity by a median of 60 percent (51 percent mean reduction) versus placebo in RRMS patients.  In addition, the study showed a favourable trend toward reducing annual relapse rates and in the number of relapse-free patients compared with placebo.  Treatment was well tolerated, with some transient and dose-dependent increases in liver enzymes reported, without clinically-evident liver damage.




In addition to the efficacy that laquinimod has shown in Phase II RRMS clinical trials, laquinimod has demonstrated potent therapeutic efficacy in preclinical models of other autoimmune diseases such as Crohn’s disease, rheumatoid arthritis, insulin-dependent diabetes mellitus, Guillain Barr Syndrome, and Lupus.  The broad profile of efficacy in animal models of inflammatory diseases suggests that laquinimod affects a pivotal pathway of inflammation and autoimmunity.  Teva has also initiated a clinical study to evaluate laquinimod for Crohn’s disease and expects to initiate the clinical development of laquinimod for Lupus Nephritis in the near future.






About the Phase III Program




Allegro (assessment of oral laquinimod in preventing progression of MS), a pivotal, global, 24/30-month, randomized, double-blind, Phase III study designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo in the treatment of RRMS, completed recruitment of more than 1,000 patient at 152 sites throughout North America, Europe, and Asia in November 2008. 




Bravo (benefit-risk assessment of Avonex® and laquinimod), a pivotal, global, 24 month, randomized, double-blind, parallel-group, placebo-controlled Phase III study designed to compare the safety and efficacy of laquinimod with placebo and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, is currently enrolling patients at centers throughout the United States, as well as Canada, Europe and Israel.  The enrollment goal is approximately 1,200 patients with RRMS.  To learn more about Teva’s ongoing clinical trials, please visit or call 1-800-840-5601 in the US and 1-800-283-0034 in Canada.    






About Multiple Sclerosis




Multiple Sclerosis (MS) is the leading cause of neurological disability in young adults.  It is estimated that more than two million people may be affected worldwide.  MS is a progressive, demyelinating disease of the central nervous system affecting the brain, spinal cord and optic nerves.  Demyelination is the destructive breakdown of the fatty tissue that protects nerve endings.






About Teva




Teva Pharmaceutical Industries Ltd.  (NASDAQ: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world’s leading generic pharmaceutical company.  The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients.  Over 80 percent of Teva’s sales are in North America and Europe.






About Active Biotech




Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer.  Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer.  Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex™ for RA.  Please visit for more information.






Active Biotech’s Safe Harbor Statement in Accordance with the Swedish Securities Market Act:


This press release contains certain forward-looking statements.  Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the company, or industry results, to differ materially from any future results, performance or achievement implied by the forward-looking statements.  The company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release. 





  1. First blog I read after wakeup from sleep today!


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s


%d bloggers like this: